Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society

Nico Melzer1 · Tobias Ruck1 · Peter Fuhr2 · Ralf Gold3 · Reinhard Hohlfeld4 · Alexander Marx5 · Arthur Melms6 · Björn Tackenberg7 · Berthold Schalke8 · Christiane Schneider-Gold3 · Fritz Zimprich9 · Sven G. Meuth1 · Heinz Wiendl1

Received: 12 December 2015 / Revised: 20 January 2016 / Accepted: 21 January 2016 / Published online: 17 February 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract Myasthenia gravis (MG) is an autoimmune antibody-mediated disorder of neuromuscular synaptic transmission. The clinical hallmark of MG consists of fluctuating fatigability and weakness affecting ocular, bulbar and (proximal) limb skeletal muscle groups. MG may either occur as an autoimmune disease with distinct immunogenetic characteristics or as a paraneoplastic syndrome associated with tumors of the thymus. Impairment of central thymic and peripheral self-tolerance mechanisms in both cases is thought to favor an autoimmune CD4+ T cell-mediated B cell activation and synthesis of pathogenic high-affinity autoantibodies of either the IgG1 and 3 or IgG4 subclass. These autoantibodies bind to the nicotinic acetylcholine receptor (AchR) itself, or muscle-specific tyrosine-kinase (MuSK), lipoprotein receptor-related protein 4 (LRP4) and agrin involved in clustering of AchRs within the postsynaptic membrane and structural maintenance of the neuromuscular synapse. This results in disturbance of neuromuscular transmission and thus clinical manifestation of the disease. Emphasizing evidence from clinical trials, we provide an updated overview on immunopathogenesis, and derived current and future treatment strategies for MG divided into: (a) symptomatic treatments facilitating neuromuscular transmission, (b) antibody-depleting treatments, and (c) immunotherapeutic treatment strategies.

Keywords Myasthenia gravis · Pathogenesis · Treatment guidelines

Introduction

Myasthenia gravis (MG) is regarded an autoimmune antibody-mediated disorder of neuromuscular synaptic transmission as (a) auto-antibody depositions are detectable at the neuromuscular junction (NMJ) [175, 176]; (b) autoantibodies from MG patients cause MG symptoms when
passively transferred into rodents [175, 176]; (c) active immunization of animals with auto-antigens reproduces the disease [59]; and (d) antibody-depleting therapies decrease the severity of MG symptoms [43, 120, 127].

The incidence of MG ranges from 0.25 to 2.0 per 1,000,000. Due to effective treatment strategies and normal life expectancy, the prevalence of MG has risen in recent years to about 72:1,000,000 (range 15–179 [15]). About 10 % of patients are children and adolescents. There is an increased familial risk for MG. Siblings or first-grade relatives of affected patients have a risk of 4.5 % for developing MG reflecting a profound genetic disposition for the disorder [71].

The clinical hallmark of MG consists of fluctuating fatigability and weakness affecting ocular, bulbar and (proximal) limb skeletal muscle groups. A pragmatic clinical classification distinguishes pure ocular myasthenia from generalized myasthenia with mild, moderate and severe manifestation. Ocular myasthenia exclusively affects the outer ocular muscles including the M. levator palpebrae and presents with ptosis and double vision. Ptosis and double vision may be transient, fluctuating or progressive during the day. Only 10–20 % of patients show muscle fatigability and weakness persistently restricted to the outer ocular muscles. The majority of patients proceed to generalized muscle fatigability and weakness within 24 months after the disease onset [135]. Generalized myasthenia is defined as any clinical affection of muscle groups other than outer ocular muscles independent of its severity.

The fluctuating muscle fatigability and weakness is illustrated by a typical decremental response of the amplitude and/or area under the curve of the elicited muscle compound action potential of the fifth compared to the first stimulus upon repetitive supramaximal stimulation of the accessory or facial nerve with a frequency of 3 Hz before and after isometric tetanic contraction [27]. The lack of an incremental response of amplitudes and areas under the curve of the compound muscle action potential upon supramaximal repetitive nerve stimulation using a frequency of 30 Hz or upon pre- and post-tetanic single stimulation proofs the post-synaptic nature of the neuromuscular transmission defect [27]. Single fiber electromyography typically shows increased jitter and intermittent conduction blocks [145, 179] reflecting instability neuromuscular transmission.

**Epidemiological, immunological, and genetic features of distinct MG subtypes**

Based on clinical, epidemiological, immunological and genetic [60, 134, 151] findings as well as thymus pathology, MG has been further sub-classified (Table 1): pure ocular MG (OMG; [135, 169]) is distinguished from generalized MG with early onset (<45 years “early-onset” MG, EOMG) and generalized MG with late onset (>45 years “late-onset” MG, LOMG). EOMG is often associated with lymphofollicular hyperplasia of the thymus, and LOMG is characterized by age-dependent involvement of the thymus. In contrast, 10–15 % of all patients do have thymoma (thymoma-associated MG, TAMG).

MG is due to a reduction of functional skeletal muscle nicotinic acetylcholine receptors (AChR) at and structural alterations of the neuromuscular endplate due to the effects of different autoantibodies. In about 85 %, autoantibodies against the AChR itself can be detected. The AChR is a pentameric ligand-gated monovalent cation channel that exists in two forms with defined stoichiometry of the homologous alpha (α), beta (β), gamma (γ), delta (δ) and epsilon (ε) subunits: the fetal AChR shows an αδβγ subunit composition, and the adult AChR shows an αεβδε subunit stoichiometry. The α-subunit contains two functionally important domains: (a) an extracellular cystein loop that mediates ligand (acetylcholine, ACh) binding [1]; and (b) an extracellular sequence to which most AChR autoantibodies are binding termed the main immunogenic region (MIR) [102, 181].

During development and following muscle innervation the γ-subunit of the fetal AChR is replaced by the ε-subunit yielding adult AChRs [146]. Normally, only skeletal muscle cells and thymic myoid cells express functional AChRs consisting of folded subunits [185]. In the normal thymus, both adult and fetal AChR are expressed by non-innervated thymic myoid cells that likely play a role in the induction of central immunological tolerance towards muscle proteins [148].

In addition, unfolded AChR subunits (but not whole functional channels [157]) are expressed by thymic epithelial cells [128], partly under the control of the autoimmune regulator (AIRE) [55]. AIRE regulates the presentation of AChR peptides by MHC molecules to developing T cells and normally supports immunological tolerance towards the AChR.

Antibodies against AChR are in part low affinity antibodies (5 %) that in contrast to high affinity antibodies (80 %) can only be detected as clusters on the cell surface in cell-based assays (CBA) but not in solubilized from in standard radioimmunoassays (RIA) [98]. Levels of antibodies against the “main immunogenic region” (MIR) of the AChR are of the complement-binding IgG1 and three type and correlate with disease severity [109]. These antibodies (Figs. 1, 2) may (a) block the receptor and (b) lead to its internalization reducing the number of available receptors in the membrane. Moreover, (c) activation of the complement cascade leads to destruction of the endplate architecture with a widened synaptic cleft (i.e.,
Table 1 Features of different subtypes of MG

|                                                          | Early-onset MG (EOMG) | Late-onset MG (LOMG) | Thymoma-associated MG (TAMG) | Anti-MuSK-Ab-associated MG (MAMG) | Ocular MG (OMG) | “Seronegative” MG (SNMG) |
|-----------------------------------------------------------|-----------------------|----------------------|-----------------------------|----------------------------------|----------------|--------------------------|
| Estimated frequency                                       | 20 %                  | 45 %                 | 10–15 %                     | 6 %                              | 15 %           | 4 %                      |
| Disease-course and manifestation                          | Generalized, disease maximum within the first 3 years | Generalized, disease maximum within the first 3 years | Generalized, more scarcely—complete remission is possible | Generalized, fasciopharyngeal focus | Ocular | Generalized |
| Age at disease onset                                       | ≤45 (50, 60) years<sup>a</sup> | >45 (50, 60) years<sup>a</sup> | Any age (primarily 40–60 years) | Any age (primarily Younger patients) | Any age | Any age |
| Male: female ratio                                        | 1:3                   | 5:1                  | 1:1                         | 1:3                              | 1:2            | n. a.                     |
| HLA-association (caucasians)                              | B8 A1 DR3 (strong)    | B7 DR2 (less strong) | DR7 (less strong)           | DR14 (strong)                    | n. a.         | n. a.                     |
| Anti-titin-ab with DR7                                     | Anti-titin-ab<sup>a</sup> | Anti-titin-ab<sup>a</sup> | Anti-titin-ab<sup>a</sup> | Anti-titin-ab<sup>a</sup> | Anti-titin-ab<sup>a</sup> | Anti-titin-ab<sup>a</sup> |
| Typical thymus pathology                                  | lymphofollicular hyperplasia (LFH) | Atrophy, involution | Thymoma Type A 5 % Type AB, B 1–3 92 % | Usually normal | No systematic data | No systemic data |
| Response to thymectomy                                     | good when performed within the first 1–2 years after diagnosis | No systematic data | Often poor | Poor | No systematic data | No systematic data |
| Response to immunotherapy                                 | +++                   | +++                  | ++                           | +                               | +++            | +                        |

<sup>a</sup> Currently there is no agreement in the literature regarding the age differentiating EOMG from LOMG [20, 104]

n. a. not applicable
the distance between the pre-synaptic acetylcholine release site and the post-synaptic endplate), increasing the distance for acetylcholine molecules to diffuse from their release sites to their receptors [109].

Upon the initiation, the humoral AChR-directed autoimmune response in MG is usually focused on single epitopes of the α-subunit of the AChR. However, during the disease course, the focus may spread also to other epitopes within the α-subunit or even other subunits or antigens [184] due to secondary involvement (i.e., professional processing and presentation) of natural AChRs derived from muscle or thymic myoid cells [28, 75, 103].

Antibodies against muscle-specific tyrosine kinase (MuSK) are of the non-complement binding IgG4 type and prevent the interaction of low-density lipoprotein receptor-related protein 4 (LRP4) with MuSK disturbing the agrin-induced architecture of the neuromuscular junction [23, 77, 85, 92, 110, 155, 156]. Antibodies against LRP4 are predominantly of the complement-binding IgG1 and 2 type and are able to inhibit the LRP4-agrin interaction and thus alter AChR clustering in muscle cells [9, 74, 125, 154, 196, 199]. Antibodies against agrin are able to inhibit agrin-induced MuSK phosphorylation and AChR clustering in muscle cells [51, 195]. The IgG subtype classification of antibodies against agrin has not yet been studied [51, 195].

AChR and MuSK antibodies usually do not occur together in a single patient [33] whereas overlap of LRP4 antibodies with both AChR and MuSK antibodies in individual patients has been reported [199]. Moreover, agrin antibodies have been also detected in combination with antibodies against MuSK, LRP4, or AChR, indicating a high incidence of autoantibodies against several neuromuscular proteins in the agrin-positive MG cases [51, 195].

Role of the thymus in distinct MG subtypes

MG may either manifest as an autoimmune disease with distinct immunogenetic characteristics or as a paraneoplastic syndrome associated with tumors of the thymus but only rarely with other malignancies [17, 106]. The thymus exhibits pathological changes in the majority of patients with AChR antibodies (most patients with OMG, EOMG, LOMG and TAMG; Table 1), which seem to be of central
importance for the impairment of central and peripheral tolerance and initiation of immunopathogenesis of MG (Figs. 1, 2) [106]. Pathological changes of the thymus have also been reported in some patients with LRP4 antibodies [199]. However, thymoma and other thymic pathologies are rarely associated with MuSK antibody MG [97, 99], and data on thymus alterations in agrin antibody MG have not yet been described [51, 195].

Almost complete elimination of autoreactive T cells is usually achieved via interactions between thymic stromal cells (epithelial cells, dendritic cells and myoid cells) expressing or presenting self-antigens and developing thymocytes. Self-tolerant T cells continue their differentiation and finally become exported to the periphery. Under physiological conditions, the thymus contains mostly thymocytes (i.e., developing T cells) and stromal cells, and the number of B cells is very small [106].

About 70 % of patients with EOMG (Fig. 1) show lymphofollicular hyperplasia (LFH), i.e., thymitis with lymphoid follicles and germinal centers within the thymus [106]. Following an unknown initial “trigger”, hyperplastic, MHC-class II expressing thymic epithelial cells (TECs) seem to present unfolded AChR subunits and activate auto-reactive CD4⁺ T cells. Early antibodies elicited by primed T cells are supposed to attack nearby myoid cells expressing folded AChRs and activate complement with subsequent release of AChR/immune complexes. These AChR/immune complexes in turn activate professional antigen presenting cells that drive further activation of auto-reactive CD4⁺ T cells leading to further activation and expansion of auto-reactive B cells with affinity maturation of their B cell receptors leading to the production of high-affinity late AChR-antibodies and subsequent epitope diversification [186].

The intrathymic autoimmune inflammatory process in EOMG seems to be self-perpetuating likely due to dysfunctional regulatory T cells that have been described in the EOMG thymus and blood [8, 173] Apparently, the autoimmune process that is initiated in the thymus can later spread to the peripheral lymphatic tissue, where skeletal muscle-derived AChR/immune complexes in regional lymph nodes and functionally defective regulatory T cells may contribute to the maintenance of EOMG [106].

10–15 % of MG patients have a thymoma and about 30 % of thymoma patients have TAMG (Fig. 2).
Thymomas are neoplasms of thymic epithelial cells (TECs) usually with mixed cortical and medullary properties [187]. According to lymphocyte content and epithelial cell features the current histological classification distinguishes type A, AB, B1, B2, and B3 thymomas [178]. More than 95% of all thymomas (except for rare type A and B3) generate polyclonal CD4⁰ and CD8⁰ thymocytes from bone marrow progenitors [178]. Such thymopoiesis plays a central role in the pathogenesis of TAMG: MG-positive but not MG-negative thymomas generate and export large numbers of mature CD4⁰ CD45RA⁺ cells to the blood [14, 79, 164]. Accordingly, thymopoietically incompetent thymic carcinomas are not associated with MG [162].

However, active thymopoiesis in thymomas occurs under conditions favoring autoimmunity: thymomas exhibit defective expression of the autoimmune regulator AIRE [166] that normally drives ‘promiscuous’ expression of peripheral tissue autoantigens (including the AChR α-subunit [55]) in thymic epithelial cells, and thymomas have reduced or absent thymic myoid cells [108]. Moreover, neoplastic epithelial cells variably express striational antigen epitopes [29], including epitopes of titin [107, 138] and various AChR subunits (but not whole receptors) [157] together with reduced levels of MHC-class II [147, 163, 187]. These altered properties of neoplastic epithelial cells may profoundly interfere with (positive and negative) selection of maturing thymocytes and the activation status of mature T cells [103, 138]. Moreover, in concert with reduced levels of AIRE [3], these alterations result in defective generation of regulatory T cells by thymomas [167]. Together, these alterations of the thymic microenvironment favor the export of substantial numbers of naïve and pre-primed auto-reactive T cells into the periphery, which are expected to gradually replace the patient’s native, more tolerant T cell repertoire in the periphery [14, 79]. In the peripheral lymphatic tissue, they apparently stimulate the pathogenic B cell response after appropriate activation. This usually happens before, but rarely also after thymoma resection [164]. This impact of the thymoma on the peripheral immune system explains why TAMG, once initiated, is self-sustaining even after complete thymoma removal (that is typically accompanied by resection of the residual thymus). Again skeletal muscle-derived AChR/autoantibody complexes processed in the absence of regulatory T cells in regional lymph nodes might perpetuate TAMG.

While the autoimmune focus of EOMG is largely on the AChR, the spectrum of autoantibody targets in individual patients with TAMG can be much broader (Table 1) [108]. The spectrum of autoantigens may include: (a) Ligand- and voltage-gated ion channels, including the skeletal muscle AChR and, much rarer, voltage-gated Ca²⁺ and K⁺ channels and other ligand-gated neurotransmitter receptors, or proteins complexed with them. (b) Striational antigens with titin and ryanodin receptors (RyR) being the major autoantibody targets. (c) Cytokines including interferon-α (IFN-α), interferon-α (IFN-α), and interleukin-12 (IL-12). This extended spectrum of autoantigens in TAMG also explains the much more frequent occurrence of other autoimmune disorders in addition to MG in these patients.

Patients with LOMG (Fig. 2) show involution and atrophy of the thymus. The lympho-epithelial tissue of the normal aging thymus is gradually replaced by fat, but residual parenchyma may continue to export some T cells at least into adulthood [34]. In LOMG, this residual lymphoepithelial tissue may rarely show signs of expansion and even infiltration, however, morphometric analysis did not reveal significant differences between thymuses of patients with LOMG and normal thymuses [165]. Thymic myoid cells tend to be sparse in LOMG [90, 182], decline with age and can reach a state of near-deficiency between the age of 60 and 70 years, with considerable interpersonal variation [139]. In addition, the number of AIRE positive cells seems to decline as well, however, with no clear difference between LOMG thymuses and age matched controls.

LOMG patients show striking immunological parallels with TAMG (Table 1): (a) autoantibodies against titin occur in 70% of patients (especially in those aged over 60 years) [14], and others have antibodies against RyR [137]. (b) Up to 40% have neutralizing antibodies against IFN-α and/or IL-12 [65, 91]. (c) More than 50% share common expansions in the peripheral T cell repertoire with TAMG patients [79, 170, 171]. Hence, immunological parallels between LOMG and TAMG are so close that it appears that aberrations in the aged thymus in LOMG mimic thymoma behavior without definite neoplasia, leading to export and possibly even activation of non-tolerant T cells [108, 186]. Substantially increased export of naïve T cells has not been observed in LOMG patients at the time of diagnosis [14, 85]. However, a small thymoma could have regressed spontaneously before the diagnosis of MG [186]. Moreover, a small population of highly potent, AChR and titin reactive T cells generated in the near absence of myoid cells inside a largely AIRE-negative atrophic thymus could become activated after export to the periphery and trigger LOMG, and a pathogenic T cell population derived from an atrophic, myoid cell-poor and AIRE-negative thymus may have accumulated in the periphery over a long period before the outbreak of LOMG, i.e., similar to rare thymoma patients who develop TAMG years after thymoma removal [164]. Once initiated, LOMG could become self-perpetuating as described above for EOMG and TAMG, i.e., by stimulatory AChR/autoantibody complexes in muscle-draining lymph nodes.
Treatment strategies for MG

Largely independent from the autoantibody status, MG is treated according to the same principles. Treatment strategies can be distinguished into (a) symptomatic treatments facilitating neuromuscular transmission and (b) immunosuppressive treatments targeting the underlying pathological immune response in MG.

Symptomatic treatments

Acetylcholinesterase inhibitors (AChEI) such as pyridostigmin bromide represent the most common symptomatic treatments. Clinical efficacy of these drugs has been underlined using electrophysiological measurements. However, their broad application in the treatment of MG is based on uncontrolled observational studies, case series as well as on good clinical practice [111, 158]. For ethical reasons placebo-controlled studies on the clinical efficacy of these compounds are prohibited.

Patients with MuSK-antibody-associated MG usually respond worse than those with nAChR-antibody-associated MG to treatment with AChEI. In these cases, higher dosages are required for symptom control often leading to increased systemic side effects [40, 132].

Pyridostigmin bromide is nowadays used for the oral long-term treatment of MG. Cholinergic side effects usually do not occur at dosages below 300 mg/day. However, during intravenous application cholinergic side effects such as bronchial spasm and hypersecretion, aggravated myasthenic muscle weakness, abdominal crampi, urinary urgency, hypersalivation and sweating, bradycardia and arterio-ventricular block, and miosis may occur and constitute cholinergic intoxication. Intravenous application of pyridostigmin bromide (up to 24 mg/day) always requires continuous monitoring in an intermediate or intensive care setting. The most frequent systemic side effects during all modes of application include gastrointestinal disturbance, diarrhea and crampi (in about 30 %), hypersalivation (in about 6 %), sweating (in about 4 %), bradycardia and arterio-ventricular block (in about 1 %) [111, 158].

Oral ambenonium chloride may be used instead of oral pyridostigmin bromide in case of bromide intolerance with gastrointestinal side effects.

Immunotherapy

The efficacy of immunosuppressive drugs in generalized MG is generally accepted. Moreover, patients with pure ocular myasthenia exhibit a reduced rate of progression to generalized MG when being under immunosuppression [96, 160].

However, only few immunosuppressive drugs have been tested in larger randomized, controlled trials providing unequivocal class I evidence for their use in MG patients. In some randomized, controlled trials positive clinical effects of some immunosuppressive drugs could even not be proven. These studies, however, exhibit methodological weaknesses which will be discussed below.

In contrast, evidence from clinical trials regarding the duration and criteria for cessation of immunotherapy is scarce [82]. Commonly, following several years of stable clinical remission the prolonged tapering of immunosuppressive drug treatment seems possible. Abrupt cessation of immunosuppression especially in a clinically unstable situation may trigger abrupt deterioration of myasthenic symptoms and myasthenic crisis [82, 188]. Indeed, most patients require life-long immunosuppressive treatment which favors opportunistic infections, lymphoma and other severe treatment-associated side effects. The overall aim of symptomatic and immunotherapy should be complete or almost complete clinical remission.

Basic immunotherapy

Glucocorticosteroids and azathioprine are first-line drugs for immunosuppression in MG. Other immunosuppressive agents can be used in case of contraindications, intolerance or insufficient clinical disease control during adequately applied first-line therapy. Second-line immunosuppressive drugs are ciclosporine A (1 positive controlled trial [174]), methotrexate (1 positive controlled trial [68]), mycophenolate mofetil (two negative controlled trials although with very short follow-up period [69, 116, 144]) and tacrolimus (1 negative controlled trial although with very short follow-up period [193]).

Glucocorticosteroids In retrospective studies, glucocorticosteroids (GCS) like prednisone, prednisolone and methylprednisolone have shown to improve clinical symptoms within several weeks to months (normally within 4–8 weeks) in about 70–80 % of patients [124, 149, 158]. Due to side effects, long-term oral GCS are usually combined with steroid-sparing immunosuppressive drugs such as azathioprine, cyclosporin A, methotrexate, mycophenolat mofetil or tacrolimus. During the first days after initiation of GCS therapy a transient deterioration of myasthenic symptoms may occur especially in patients with a pronounced affection of bulbar muscle groups [6].

Three different dosing regimens are currently used in clinical practice:

1. Initial dosage of 10–20 mg/day prednisone equivalent and dosage increase of 5 mg/day per week until a stable remission is reached (at about 1 mg/day/kg
intravenous methylprednisolone pulse-therapy using metabolized rapidly to the cytotoxic and
Azathioprine is a purine analogue that is used immunosuppressive agent for treatment of MG [13, 66, 105, 112]. Azathioprine (AZA) is the most frequently systematic data are lacking. Needs to be validated in individual patients as long as application in the low dose range, the usefulness of which cannot be expected before several months. However, a steroid-sparing effect of AZA during long-term treatment has been proven [39, 66, 159]. The combination of AZA and prednisolone is more effective, as longer states of remission and less side effects are encountered as compared to respective monotherapies [123]. In 10–20 % of patients the combination of AZA and GCS does not lead to sufficient clinical stabilization or remission requiring GCS at dosages of more than 7.5 mg/day prednisolone equivalent and in the long term requiring other immunosuppressive treatment strategies (therapy resistance). The abrupt cessation of AZA may trigger re-occurrence of myasthenic symptoms up to a myasthenic crisis even in patients in complete and stable clinical remission [82, 114]. In about 80 % of patients treated with AZA an increase of the mean corpuscular volume (MCV) of the red blood cells can be observed, which is more pronounced and more frequent in treatment responders compared to non-responders. Due to its mechanism of action, AZA leads to a potentially reversible lymphopenia under steady-state conditions. Absolute lymphocyte counts should be in the range of 600–1200/μl with total leukocyte counts being well above 3500/μl.

AZA is a prodrug that is metabolized by the glutathione-s-transferase into its active metabolite 6-mercaptopurine und 1-methyl-4-nitro-5-thioimidazol. 6-Mercaptopurine in turn is further metabolized by the xanthinoxidase or the thiopurin-S-methyltransferase (TPMT). Inhibitors of the xanthinoxidase such as allopurinol and others inhibit the metabolism of azathioprine. With this comedication azathioprine may only be used in a reduced dosage of 25 % of the standard dosage (i.e., 0.5–0.75 mg/day/kg body-weight) to prevent myelotoxic side effects. Instead of xanthinoxidase inhibitors, other drugs such as benzbro-marone or probenecide may be used for lowering uric acid levels in case AZA is required.

In a small number of patients (<1 %) acute severe side effects like nausea and vomiting, gastrointestinal disturbance with diarrhea and cardiocirculatory depression may occur as idiosyncratic immediate reaction and prevent patients from further treatment with AZA [81]. To exclude such idiosyncratic reactions a single oral test dosage of 50 mg prior to the initiation of long-term treatment with AZA can be recommended to detect such side effects.

**Azathioprine** Azathioprine (AZA) is the most frequently used immunosuppressive agent for treatment of MG [13, 66, 105, 112]. Azathioprine is a purine analogue that is metabolized rapidly to the cytotoxic and immunosuppressant derivatives 6-mercaptopurine and thioinosinic acid. The latter inhibits purine synthesis, and thus impairs activation and proliferation and causes apoptosis of T cells and B cells due to their lack of metabolic pathways for nucleotide salvage (‘recycling’). Treatment is initiated using 2–3 mg/day/kg bodyweight and maybe reduced during the treatment course in case of a clinically stable remission to about 2.5 mg/day/kg bodyweight and further to 1 mg/day/kg bodyweight. Treatment effects can be expected before several months. However, a steroid-sparing effect of AZA during long-term treatment has been proven [39, 66, 159]. The combination of AZA and prednisolone is more effective, as longer states of remission and less side effects are encountered as compared to respective monotherapies [123]. In 10–20 % of patients the combination of AZA and GCS does not lead to sufficient clinical stabilization or remission requiring GCS at dosages of more than 7.5 mg/day prednisolone equivalent and in the long term requiring other immunosuppressive treatment strategies (therapy resistance). The abrupt cessation of AZA may trigger re-occurrence of myasthenic symptoms up to a myasthenic crisis even in patients in complete and stable clinical remission [82, 114]. In about 80 % of patients treated with AZA an increase of the mean corpuscular volume (MCV) of the red blood cells can be observed, which is more pronounced and more frequent in treatment responders compared to non-responders. Due to its mechanism of action, AZA leads to a potentially reversible lymphopenia under steady-state conditions. Absolute lymphocyte counts should be in the range of 600–1200/μl with total leukocyte counts being well above 3500/μl.

AZA is a prodrug that is metabolized by the glutathione-s-transferase into its active metabolite 6-mercaptopurine und 1-methyl-4-nitro-5-thioimidazol. 6-Mercaptopurine in turn is further metabolized by the xanthinoxidase or the thiopurin-S-methyltransferase (TPMT). Inhibitors of the xanthinoxidase such as allopurinol and others inhibit the metabolism of azathioprine. With this comedication azathioprine may only be used in a reduced dosage of 25 % of the standard dosage (i.e., 0.5–0.75 mg/day/kg body-weight) to prevent myelotoxic side effects. Instead of xanthinoxidase inhibitors, other drugs such as benzbro-marone or probenecide may be used for lowering uric acid levels in case AZA is required.

In a small number of patients (<1 %) acute severe side effects like nausea and vomiting, gastrointestinal disturbance with diarrhea and cardiocirculatory depression may occur as idiosyncratic immediate reaction and prevent patients from further treatment with AZA [81]. To exclude such idiosyncratic reactions a single oral test dosage of 50 mg prior to the initiation of long-term treatment with AZA can be recommended to detect such side effects.
In case of a genetically determined low TPMT activity, AZA leads to unexpectedly strong myelosuppression shortly after treatment initiation. Testing for TMPT activity or TPMT genotype can be performed prior to treatment initiation: (a) patients completely lacking TMPT activity (frequency 1:300) or those homozygous for distinct TPMT single nucleotide polymorphisms cannot be treated with AZA. This genotype however is very rare (about 0.5 %) [56]. Whether this genotype is associated with the above mentioned idiosyncratic immediate reaction is currently unclear. (b) In cases of exceedingly high TPMT activity, AZA may be rapidly metabolized without yielding a clinical effect.

An increased risk of malignancies under AZA treatment for less than 10 years is not evident [25, 189]. In patients with MG, rare cases of hematological malignancies and opportunistic infections have been reported [73, 114]. Moreover, an increased incidence of cutaneous hyperkeratosis and skin cancer under azathioprine has been reported, probably due to increased photosensitivity [122]. Regular skin examinations are recommended in patients under long-term therapy with azathioprine. In case of the occurrence of generalized warts, or multiple basalioma, AZA treatment must be reduced or changed to a different drug. A few cases of acute phototoxic reactions have been reported under intense solar irradiation.

**Ciclosporin**

Ciclosporin A (CSA) has proven its efficacy in patients with MG in one placebo-controlled clinical trial providing class I evidence [174].

Ciclosporin binds to the cytosolic protein cyclophilin in lymphocytes and thereby inhibits the calcium-calmodulin induced activation of calcineurin following antigen-receptor stimulation that is required for antigen-specific lymphocyte activation, differentiation and exertion of effector functions.

Compared to the above mentioned clinical trial (CSA monotherapy using 6 mg/day/kg bodyweight in two single dosages) CSA is currently in clinical use in combination with GCS at a lower dosage of initially 3–4 mg/day/kg bodyweight, followed by a reduction to 2–2.5 mg/day/kg bodyweight in two single dosages. Treatment monitoring should be performed via blood levels (trough level at the end of a dosing interval of 12 h). Compared to AZA, the clinical effect of CSA occurs more rapidly, i.e., mostly within 4–6 weeks. However, CSA has a much broader spectrum of side effects that occur depending on its dosage and include opportunistic infection, myelosuppression, gingival hyperplasia and gastrointestinal disturbance, as well as nephrotoxicity with hyperkalemia (requiring monitoring of renal function during therapy) and arterial hypertension. Special side effects include tremor, headache, increased propensity of epileptic seizures and rarely reversible posterior leukoencephalopathy syndrome. Moreover, CSA exhibits numerous interactions with other drugs which is especially relevant in elderly, multimorbid patients and requires intense drug monitoring.

**Methotrexate**

Methotrexate (MTX) has been used for several decades now as a treatment for MG. MTX competitively inhibits dihydrofolate reductase (DHFR) with an affinity of about 1000-fold that of dihydrofolate. Dihydrofolate reductase catalyzes the conversion of dihydrofolate to the active metabolite tetrahydrofolate involved in the de-novo synthesis of purine and pyrimidine nucleotide synthesis. Methotrexate, therefore, inhibits the synthesis of DNA, RNA, and proteins and thus reduces proliferation among others of lymphocytes. Most prominent side effects of MTX include hepatotoxicity, ulcerative stomatitis, leukopenia, anemia, infections, nausea and vomiting, abdominal pain, acute pneumonitis, and rarely pulmonary fibrosis and kidney failure.

Despite its long-term use in patients with MG, controlled clinical trials were lacking until recently. A recent clinical trial compared MTX (17.5 mg/week) in 24 patients with generalized MG with AZA (2.5 mg/day/kg bodyweight) regarding its steroid-sparing effect and showed an equivalent effect within a treatment period of 2 years [68]. MTX at a dosage of 7.5–25 mg/week in combination with folic acid can thus be regarded as a second-line drug for the treatment of MG. Due to its less frequent interactions with other drugs, MTX may be preferred over CSA especially in older multimorbid patients [76].

**Mycophenolate mofetil**

Mycophenolate mofetil (MMF) non-competitively inhibits the inosin-monophosphate-dehydrogenase (IMPDH) and thus the de-novo synthesis of purine nucleotides which are required especially for cell proliferation in lymphocytes.

The most prominent side effects of MMF include chronic diarrhea, hemolytic anemia and edema. Several cases of progressive multifocal leukoencephalopathy have been reported on the treatment with MMF [183]. Moreover, MMF has proved to be teratogenic. Hence, MMF-treatment should be stopped in case of planned pregnancy at least 4 months before conception. In case of unplanned pregnancy, MMF should be stopped immediately and followed by gynecologic counseling [78].

MG patients showed clinical improvement with steroid-sparing effect under treatment with MMF in several observational cohort studies on a dosage of 1500–2000 mg/day under drug monitoring [21, 64, 69]. However, in two clinical phase III trials, MMF was not superior to prednisone as an initial therapy [116] and did not show any steroid-sparing effect when studied over a period of 9 months [144]. Considering the latency of
clinical effects known to occur under MMF therapy, the follow-up period of no longer than 36 weeks in the two phase III studies seems quite short. Moreover, the treatment effect of prednisone was unexpectedly good. Hence, MMF effects seem to be underestimated based on methodological issues in these trials. Consistently, subsequent uncontrolled cohort studies again a beneficial effect of MMF as monotherapy or in combination with prednisone could be shown after 6 months of treatment [69].

**Tacrolimus (TCM)**  Tacrolimus (TCM) like CSA is a calcineurin inhibitor effectively inhibiting antigen-specific lymphocyte activation, differentiation and exertion of effector functions in lymphocytes. The efficacy of TCM compared to CSA is 10–100 times stronger. Side effects are the same as those occurring under CSA and exhibit a strong dosage dependency. TCM was developed in Japan and is licensed for the treatment of MG there [118, 172]. Several open clinical studies and smaller case series report beneficial clinical effects of TCM (3–5 mg/day) in patients with therapy-refractory MG [41, 94, 115, 117]. In a multicenter, open cohort study in 79 patients with MG, low-dosage TCM (0.1 mg/day/kg bodyweight) could replace combination therapy consisting of CSA and prednisolone and provide good clinical stabilization including regression of nAChR-Ab titers [130, 131]. A randomized, placebo-controlled clinical trial in 80 patients with MG with minimal clinical disease under an oral prednisolone therapy (10–20 mg/day) studied the steroid-sparing effect of TCM (3 mg/day) over a period of 28 weeks. The oral prednisolone therapy was reduced stepwise starting after 4 weeks of TCM treatment. However, no significant difference was detected between TCM and placebo regarding the mean oral prednisolone dosage during the last 12 weeks of the follow-up period. Due to the study population and the short follow up, this study provides little evidence on the long-term efficacy of TCM in patients with MG and insufficient treatment response on the GCS-therapy [193]. Like CSA, TCM is nephro- and neurotoxic and exhibits multiple drug interactions.

**Escalation therapy**

**Rituximab and other monoclonal antibodies**  A number of case reports and case series report on the clinical efficacy of rituximab, a monoclonal anti-CD20 antibody depleting circulating B lymphocytes in patients with severe therapy-refractive MG. However, data from randomized controlled trials is still missing. A meta-analysis was recently performed of 15 uncontrolled observational studies including a total of 168 patients [125 females and 43 males; 91 MG patients with AChR antibodies, 70 MG patients with MuSK antibodies, and 7 MG patients without AChR or MuSK antibodies (“double seronegative”)] [87]. The median follow-up was 16 months for AChR antibody+ patients, 26 months for MuSK antibody+ patients and 12 months double seronegative patients. The dosing regimen of rituximab varied between studies: 137 patients received 4 × 375 mg/m² of rituximab, 12 patients received 500 mg on day 1 and 8, and 8 patients received 1000 mg on day 1 and 15. The remaining 11 patients underwent different treatment regimens. The overall response rate was reported to be 83.9 %. In particular the response rate was higher in the MuSK antibody+ patients (88.8 %) compared to AChR antibody+ patients (80.4 %) and double seronegative patients (85.6 %). However these differences between different MG patients groups were not statistically significant. Rituximab proved to be efficacious in all different therapeutic regimens. It has been hypothesized that IgG4 antibodies against MuSK are produced almost exclusively by CD20+ short-lived plasma cells in contrast to IgG1 and 3 antibodies against AChR which seem to be synthesized by CD20- long-lived plasma cells. This might explain the trend higher efficacy of rituximab in MuSK antibody+ compared to AChR antibody+ patients [32, 84]. In MuSK antibody+ patients clinically responsive to rituximab antibody titers are typically lowered whereas some dissociation between antibody titers and clinical response to rituximab was observed in AChR antibody+ patients [19]. Moreover, an inverse correlation trend between disease duration and response rate to rituximab was observed which also did not reach statistical significance. This trend was also attributed to the pool of long-lived plasma cells increasing with disease duration and thus leading to a diminishing therapeutic effect of rituximab. Adverse effects were reported in 7/168 patients (4.2 %): infections in 4 patients (herpes zoster 1, giardiasis 1, bronchitis 1, pneumonia 1), prolonged B cell depletion in 2 patients, and heart failure in 1 patient). No case of treatment-associated progressive multifocal leukoencephalopathy was reported. Hence, data from this meta-analysis of uncontrolled observational studies support the use of rituximab in patients with refractory MG. Nevertheless, multicentre randomized-controlled trials are needed to definitely establish the efficacy and safety of rituximab in MG.

Eculizumab is a humanized monoclonal antibody, blocking the formation of terminal complement complex by specifically preventing the enzymatic cleavage of complement 5 (C5). A recent, randomized, double-blind, placebo-controlled, crossover phase II trial studied the clinical efficacy of eculizumab in 14 patients with severe, refractory generalized MG [83]. Patients received 4 weekly intravenous infusions of eculizumab 600 mg or placebo (induction phase) followed by seven additional two weekly

© Springer
| Substances                  | Dose                                           | Side effects                                                                 | Contraindications and special remarks                                                                 |
|-----------------------------|------------------------------------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| **Cholinesterase inhibitors** |                                               |                                                                              |                                                                                                        |
| Pyridostigmin bromide (approved) | Single dose orally: 30–60 mg max. 360 mg/day | Stimulation of muscarinic AChR (smooth muscles, gland secretion): stomach cramps, nausea, vomiting, anorexia, diarrhea, urinary urgency, salivation/lacrivation, sweating, bronchial secretion, accommodation errors, miosis, bradycardia (rarely AV block), hypertension stimulation of nicotinic AChR (skeletal muscles): muscle fasciculation, spasms, muscle weakness (depolarization block) | Absolute contraindications: asthma bronchiale, prostatitis hypertrophy, decompensated heart insufficiency, acute myocardial infarction, thyrotoxicosis relative contraindications: pregnancy, breast-feeding |
| Ambenonium chloride (off label) | Single dose orally 5–10 mg max. 40 mg/day | Fewer gastrointestinal side effects than pyridostigmin | Analog to pyridostigmin |
| **Immunosuppressants**      |                                               |                                                                              |                                                                                                        |
| Glucocorticosteroids: prednisone prednisolone methylprednisolone (approved) | Oral therapy: 0.5–1.5 mg/kg | Gain of weight, cushingoid phenotype, acne, diabetes, susceptibility to infections and thrombosis, hypertension, hypokalaemia, edema, psychosis, osteoporosis with the risk of fractures, aseptic bone necrosis, cataract, glaucoma, psychological disorders (euphoria/depression), insomnia, steroid myopathy, gastric and duodenal ulcer | Severe infections, malignant diseases, severely reduced immune defense, pregnancy, breast-feeding severe infections, manifest gastric and duodenal ulcer, severe osteoporosis, psychiatric disorders, uncontrolled hypertension, uncontrolled diabetes |
| Azathioprine (approved)     | Induction dose: 2–3 mg/day/kg                  | Susceptibility to infections, bone marrow depression (leukopenia, thrombopenia, rarely anemia), nausea, vomiting, diarrhea, fever, allergic reaction, hepatotoxicity, arthralgia, myalgia, alveolitis, pancreatitis, skin exanthema | Pregnancy: azathioprine may be prescribed in case of an appropriate indication. If a female patient is stable on azathioprine therapy should not be stopped Breast-feeding: azathioprine therapy does not exclude breast feeding. No vaccinations with live vaccines! Success of vaccinations in general is uncertain Simultaneous admission of allopurinol or other xanthinoxidase inhibitors leads to myelotoxicity and agranulocytosis—dose reduction to 25 % of azathioprine or switch from allopurinol to probenecid or benz-bromaron severe bone marrow and liver and kidney damage |
| Ciclosporin A (off-label)    | 2 (–5) mg/day/kg in two single doses       | Hypertonia, nephrotoxicity (nephropathy, hyperkalaemia), CNS-toxicity (tremor, paresthesia, seizures), posterior reversible encephalopathy syndrome, hepatotoxicity, hirsutism, gingiva hyperplasia, secondary malignancies, infections | Kidney failure, severe infections, malignant diseases, severely reduced immune defense, pregnancy, breast-feeding |
| Methotrexate (off-label)     | 7.5–15 mg once per week max. 25 mg once per week in combination with folic acid (5 mg) 24 h after application | Hepatotoxicity, bow marrow depression, gastrointestinal symptoms, stomatitis, ulcers, exanthema, loss of hair, hyperuricemia, kidney failure, cystitis, lung fibrosis, cutaneous vasculitis, photosensitivity, psychiatric disorder, osteoporosis | Liver or kidney failure, severe infections, malignant diseases, severely reduced immune defense, pregnancy, breast-feeding, bone marrow depression, florid gastrointestinal ulcer |
| Mycophenolate mofetil (off-label) | 0.5–3 g/day in two single doses (mostly 2 x 1 g/day) | Gastrointestinal symptoms (nausea, vomiting, diarrhea, ulcers, gastrointestinal bleeding), bone marrow depression (leukopenia, anemia, thrombocytopenia), infections, risk for lymphoma under long-term therapy, progressive multifocal leukoencephalopathy (PML) | Severe infections, malignant diseases, severely reduced immune defense, pregnancy, breast-feeding |
intravenous infusions of eculizumab 900 mg or placebo (maintenance phase). Six of seven patients treated with eculizumab for 16 weeks (86%) achieved the primary endpoint of a 3-point reduction in the quantitative myasthenia gravis (QMG) score. Moreover, the overall change in mean QMG total score was significantly different between eculizumab and placebo, and the overall change in mean QMG total score from baseline was found to be significantly different between eculizumab and placebo. Eculizumab was well tolerated [83]. Hence, this trial supports a role also for eculizumab in patients with severe, refractory generalized MG. A Phase III trial of eculizumab in refractory MG is currently ongoing [126].

Clinical experience with other therapeutic monoclonal antibodies now in broader use in multiple sclerosis such as anti-CD52/alemtuzumab [22, 24] and anti-IL2R/daclizumab [54, 58] are sparse in patients with MG and should be considered in individual rare cases only.

**Cyclophosphamide** Cyclophosphamide (CPP) is a nitrogen mustard alkylating agent adding an alkyl group to DNA. This interferes with DNA replication by forming intrastrand and interstrand DNA crosslinks. CPP can be applied in cases of severe MG following the failure of standard therapy. Moreover, CPP can be applied in patients requiring repetitive immunoadsorption or plasmapheresis based on several smaller controlled case series [35, 100]. In severe and otherwise treatment resistant life-threatening MG, CPP can be used as ultima ratio as positive clinical evidence exist for several treatment regimens:

1. CPP pulse therapy: 500 mg/m² body surface area every 4 weeks until remission under co-medication with mesna, based on a prospective, randomized, double-blinded study [31].

2. Immuno- or myeloablative CPP therapy: 50 mg/day/kg bodyweight on 4 consecutive days followed by GCSF based on several smaller case studies [36, 57, 100] or followed by auto- or allogeneic stem cell transplantation [168].

The cumulative dosage and duration of treatment should be documented due to the increasing risk of disorders of fertility in both sexes and the risk of malignoma (about 1%, depending on the cumulative dosage and duration of therapy). In single cases, a cumulative dosage of 50–70 g can be reached. As these values are reached much faster upon oral application compared to intravenous application of CPP, the later should be the preferred route of administration. Complications of CPP therapy may among others include malignoma, lung fibrosis, cardiomyopathy and dermatotibroma.

For an overview on treatment options for MG please refer to Table 2.
**Intervention therapy**

The following therapeutic measures are applied for the prevention and therapy of myasthenic crisis and in special situations such as instable MG during pregnancy and distinct single cases of therapy resistant myasthenia with severely disabling symptoms.

**Intravenous immunoglobulins (IVIG)**

Intravenous immunoglobulins (IVIG) consist of pooled polyclonal immunoglobulins derived from several thousand healthy donors. The precise mechanism by which IVIGs suppress autoimmune inflammation has not been definitively established but is likely to involve a plethora of molecular effects via their Fab- or Fc-fragments [52]. Adverse effects of IVIG include headache, hypertension, allergic/anaphylactic reactions (especially in IgA-deficient patients), dermatitis, infection (HIV or viral hepatitis), pulmonary edema from fluid overload, due to the high colloid oncotic pressure of IVIGs, venous thrombosis, aseptic meningitis, and hemolysis.

IVIG should be applied at a dosage of 0.4 g/day/kg bodyweight on 5 consecutive days [86], alternatively 1 g/day/kg bodyweight on 2 consecutive days [7, 50, 198]. IVIG have been shown to be similarly effective compared to plasmapheresis and immunoadsorption in shortening the time of mechanical ventilation during myasthenic crisis [46, 49].

Moreover, IVIG may be used for clinical stabilization previous to operations (including thymectomy) or before start of an intravenous high-dosage GCS pulse therapy in case of severe MG. Clinical response rate in several open clinical studies was in the range of 80%.

For the use of IVIG in situations other than myasthenic crisis as induction therapy or as maintenance therapy—either alone or as add-on therapy to immunosuppressive drugs—no data is available from randomized controlled trials. IVIG, however, may be used for this purpose (initially 5 × 0.4 g/day/kg bodyweight and subsequently 1 × 0.4 g/day/kg bodyweight every 4–8 weeks) over a longer period of time [38, 72, 161]. Single patients with therapy resistant myasthenic symptoms seem to profit from long-term therapy with IVIG [111, 112]. IVIG may also be used in MG patients with contraindications against other immunosuppressive agents (especially GCS).

**Plasmapheresis and immunoadsorption**

Via therapeutic plasma exchange (PE) or plasmapheresis, plasma is separated from corpuscular blood constituents and replaced with a substitution fluid. PE is thus a non-specific treatment modality with elimination of the entire plasma. The therapeutic effect is based on the removal of circulating, pathogenic immune factors, including autoantibodies. In contrast, immunoadsorption (IA) is a more selective technique for removing IgG antibodies by binding to a specific matrix (e.g., protein A or tryptophan) [95, 150, 180].

Plasmapheresis is successfully used as a treatment of myasthenic crisis [30, 127, 142]. Moreover, plasmapheresis can be used in situations of therapy resistance for the stabilization of patients before operations (including thymectomy) or prior to the initiation of high-dosage GCS pulse therapy in cases of severe MG. Typically, 6–8 treatments (each with treatment of 1–1.5 times the plasma volume every other day) are performed until clinical remission is reached. Without accompanying immunosuppression the clinical effect lasts for several weeks only due to the (re-)synthesis of pathogenic autoantibodies [70, 119]. Following every single treatment, a substitution of human albumin is required, and in case of secondary immunoglobulin deficiency (IgG < 150 mg/dl) substitution with polyvalent IgG can be performed. The depletion also of coagulation factors limits the treatment frequency and needs to be considered in situations of treatment with other anticoagulant drugs [48]. In myasthenic crisis, plasmaphereses and IVIG seem to be equally effective and can be used equivalently [26, 47, 158]. A randomized controlled study did not find a significant difference between both therapeutic strategies [46]. Moreover, a controlled cross-over study and a retrospective cohort study did also show no significant difference between these treatments [38, 72, 133, 161]. A recent comparative study in 84 patients with moderate to severe MG (QMGS ≥ 10.5) and clinical exacerbation also showed a similar efficacy of IVIG and plasmapheresis regarding the primary endpoint of reduction of the QMGS (69 % for IVIG and 65 % for plasmapheresis) as well as secondary clinical and electrophysiological endpoints for a follow-up period of 60 days [10].

Immunoadsorption is nowadays frequently used instead of plasmapheresis both for the treatment of myasthenic crisis as well as for the maintenance therapy of patients with insufficient disease control under or contraindications for standard immunosuppressive treatment [191, 194]. Immunoadsorption has been shown to be equally effective in the treatment of MG compared to plasmapheresis [93]. Advantages of immunoadsorption include the lack of need for substitution of plasma proteins and coagulation factors, providing the option for the rapid treatment of much higher plasma volumes (2–2.5 times the plasma volume every day) as compared to plasmapheresis. Moreover, complications and side effects of immunoadsorption seem to be significantly reduced compared to plasmapheresis [93].
Thymectomy

Thymectomy in MG patients should always be performed under otherwise stable clinical conditions, i.e., following an efficient pre-treatment using GCS and other immunosuppressive measures and/or plasmapheresis/immunoadsorption or IVIG which reduces the perioperative mortality to <1% [61]. The clinical effect of thymectomy usually appears retrospectively after several years in an individual patient [61].

Thymomectomy for thymomatous MG

In case of a thymoma, indication for thymomectomy exists independent of the presence or clinical severity of accompanying MG or other autoimmune conditions.

Thymectomy for non-thymomatous AChR antibody associated MG

Given the role of the thymus in the immunopathogenesis of AChR antibody-associated MG, thymectomy has been considered a treatment option as early as 1942 [67]. However, randomized controlled trials on the efficacy of thymectomy per se and in comparison to standard immunosuppressive treatment in MG are currently not available [18]. The results of an ongoing multi-center, single-blind, randomized phase III trial comparing extended transternal thymectomy to no thymectomy in non-thymomatous AChR antibody associated MG patients receiving prednisone (MGTX trial [12, 190]) are expected for 2016.

Until the results of the MGTX trial are available, thymectomy should be considered in the following clinical situations: (a) Thymectomy may be applied in patients with non-thymomatous generalized MG for which evidence exists according to a meta-analysis [61]. (b) Patients with non-thymomatous ocular myasthenia may undergo thymectomy based on a single case decision due to a lack of sufficient evidence from clinical trials [11]. It is supposed that thymectomy in ocular myasthenia without thymoma might prevent generalization of myasthenic symptoms during the course of the disease [89].

Patients at the age of 15–50 years with generalized AChR antibody-associated MG without thymoma seem to predominantly benefit from thymectomy performed within 1–2 years after disease onset [61, 152]. However, these age limits are arbitrary and some experts do not consider them strict [80]. Children and adolescents at the age of 5–14 years with AChR antibody-associated MG without thymoma are preferred to undergo thymectomy only after insufficient response to symptomatic and immunosuppressive treatment [16, 45] because of the role of the thymus in the development of the immune system [177]. However, some studies indicate that thymectomy at 1.5 years of age apparently does not impair immunological function [4, 136, 177].

Thymectomy for non-thymomatous MuSK antibody associated MG

In contrast to AChR antibody-associated MG, thymic pathology is relatively rare [63, 97, 99, 197] in patients with MuSK antibody-associated MG. Accordingly, one study [42] could not prove any effect of thymectomy in 15 MuSK antibody-positive patients, whilst MuSK antibodies predicted a poor outcome of thymectomy in another study [129]. Hence, available evidence suggests that in general thymectomy should not be recommended in MuSK antibody-associated MG. However, as few MuSK antibody-positive patients have been reported to apparently improve following thymectomy it may be considered in single cases with otherwise poor disease control [42, 143].

Thymectomy for non-thymomatous seronegative MG

A retrospective cohort study of thymectomy reported similar post-operative results in AChR antibody-negative and AChR antibody-positive MG patients with a follow-up of at least 3 years [62]. Remission or improvement after thymectomy occurred in 57% of AChR antibody-negative patients and in 51% of AChR antibody-positive patients. Hence, thymectomy is recommended for patients with generalized MG without detectable AChR and MuSK antibodies similar to those patients with AChR antibodies.

Technique of thymectomy

Standard procedure for thymectomy used to be the extended transternal thymectomy with excision of the whole thymus and retrosternal adipose tissue aiming at a maximal thymectomy [88]. However, minimal invasive interventions are increasingly applied [5, 53, 121, 140, 141, 192]. While these studies cannot be compared to each other due to pronounced confounding factors, the reported effects on therapeutic and clinic surrogates seem to be equivalent [113]. Hence minimally invasive thymectomy represents an option alternative to the gold standard of extended transternal thymectomy and is used by an increasing number of centers.

A suggested treatment regimen is depicted in Table 3.
Conclusion

Myasthenia gravis (MG) is an autoimmune antibody-mediated disorder of neuromuscular synaptic transmission. The clinical hallmark of MG consists of fluctuating fatigability and weakness affecting ocular, bulbar and (proximal) limb skeletal muscle groups. MG may either occur as an autoimmune disease with distinct immunogenetic characteristics or as a paraneoplastic syndrome associated with tumors of the thymus. Impairment of central thymic and peripheral self-tolerance mechanisms in both cases is thought to favor an autoimmune CD4+ T cell-mediated B cell activation and synthesis of pathogenic high-affinity autoantibodies of either the IgG1 and 3 or IgG4 subclasses. These autoantibodies bind to the nicotinic acetylcholine receptor (AchR) itself, or muscle-specific tyrosine-kinase (MuSK), lipoprotein receptor-related protein 4 (LRP4) and agrin involved in clustering of AchRs within the postsynaptic membrane and structural maintenance of the neuromuscular synapse.

Treatment strategies for MG can be divided into: (a) symptomatic treatments with AChEIs facilitating neuromuscular transmission, (b) antibody-depleting treatments (IVIG, plasmapheresis, or immunoadsorption) for acute therapeutic intervention, and (c) immunotherapeutic treatment strategies (GCS plus azathioprine, ciclosporin A, methotrexate, mycophenolate mofetil, or tacrolimus for basic therapy, cyclophosphamide or rituximab for escalation therapy) for maintenance therapy. Experimental therapies such as other monoclonal antibodies, proteasom inhibitors, immune—or myeloablation, and stem cell transplantation are used in selected rare cases only. Given the role of the thymus in the immunopathogenesis of EOMG and TAMG, thymectomy should be performed following sufficient clinical stabilization.

Acknowledgments We would like to thank Heike Blum for excellent graphical illustration of the manuscript.

Author contributions NM, PF, RH, AM, AM, BT, BS, CSG, FZ, and HW served as members of the consensus committee for the clinical guidelines “Diagnostik und Therapie der Myasthenia gravis und des Lambert-Eaton-Syndroms” of the German Neurological Society (DGN). NM, TR, SGM and HW performed initial adoption and translation of the clinical guidelines. AM contributed distinct expertise on the role of the thymus in myasthenia gravis. All authors contributed to and approved the final manuscript.

Compliance with ethical standards

Conflicts of interest N. M. has received honoraria for lecturing and travel expenses for attending meetings from Biogen Idec, GlaxoSmithKline, Genzyme, Teva, Novartis Pharma, Bayer Healthcare, and Fresenius Medical Care and has received financial research support from Fresenius Medical Care. T. R. has received travel expenses and financial research support from Genzyme and Novartis and has received honoraria for lecturing from Genzyme, Biogen and Teva. P. F. has received honoraria for lecturing and travel expenses for attending meetings from Mepha Pharma; has served/services as a consultant for GE Healthcare and UCB; and has received/receives financial research support from Roche. R. G. has received honoraria for lecturing and travel expenses for attending meetings from Baxter, Bayer Schering, Biogen Idec, CSL Behring, Genzyme, Merck Serono, Novartis and TEVA; has served/serves as a consultant for Baxter, Bayer Schering, Biogen Idec, CSL Behring, Genzyme, Merck Serono, Novartis and TEVA; and has received/receives financial research support from Bayer Schering, Biogen Idec Genzyme, Merck Serono, Novartis and TEVA. R. H. has received honoraria for lecturing and travel expenses for attending meetings from Bayer/Schering, Biogen Idec; CSL Behring, Genzyme, Merck Serono, Morphosys, Novartis, Sanofi, Teva; has served/services as a consultant for Bayer/Schering, Biogen Idec, CSL Behring, Genzyme, Merck Serono, Morphosys, Novartis, Sanofi and Teva; and has received/receives financial...
research support from Bayer/Schering, Biogen Idec, Novartis, Sanofi-Genzyme, A. Ma. Has nothing to declare. A. Me. has received financial research support from Medical Park AG. B. T. received honoraria for lecturing and travel expenses for attending meetings from Bayer Vital, Biogen Idec, CSL Behring, Genzyme, Grifolis, Merck Serono, Octapharma and Sanofi Aventis; has served/serves as a consultant for Bayer Vital, Biogen Idec, CSL Behring, Genzyme, Grifolis, Merck Serono, Octapharma and Sanofi Aventis; and receives/received financial research support from Bayer Vital, Biogen Idec, Novartis and Sanofi Aventis. B. S. received honoraria for lecturing and travel expenses for attending meetings from Media, Valeant and Baxter. C. S.-G. has nothing to declare. F. Z. has nothing to declare. S.G.M. received honoraria for lecturing and travel expenses for attending meetings and has received financial research support from Bayer, Biogen Idec, Sanofi-Aventis, Bayer Schering, Merck Serono, Novo Nordisk, Genzyme, MSD and Teva. H.W. has received honoraria for lecturing and travel expenses for attending meetings from Bayer Schering Pharma, Biogen Idec/Elan Corporation, Sanofi-Aventis, Merck Serono, and Teva Pharmaceutical Industries Ltd.; has served/serves as a consultant for Merck Serono, Medac, Inc., Sanofi-Aventis/Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Novartis, and Novo Nordisk; and receives/received financial research support from Bayer Schering Pharma, Biogen Idec/Elan Corporation, Sanofi-Aventis, Merck Serono, and Novo Nordisk.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89:73–120
2. Arsura E, Brunner NG, Namba T, Grob D (1985) High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 42:1149–1153
3. Ashenbrenner K, D’Cruz LM, Vollmann EH, Hinterberger M, Emmerich J, Swee LK, Rolink A, Klein L (2007) Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire + medullary thymic epithelial cells. Nat Immunol 8:351–358
4. Ashraf VV, Taly AB, Veerendrakumar M, Rao S (2006) Myasthenia gravis in children: a longitudinal study. Acta Neurol Scand 114:119–123
5. Bachmann K, Burkhardt D, Schreiter I, Kafi J, Busch C, Thayssen G, Izbicki JR, Strate T (2008) Long-term outcome and quality of life after open and thoracoscopic thymectomy for non-thymomatous myasthenia gravis. J Thoac Surg 22:2470–2477
6. Bae JS, Go SM, Kim BJ (2006) Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci 13:1006–1010
7. Bain PG, Motomura M, Newsom-Davis J, Mishab SA, Chapel HM, Lee ML, Vincent A, Lang B (1996) Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47:678–683
8. Balandina A, Lecart S, Dartevelle P, Saoudi A, Berrih-Aknin S (2005) Functional defect of regulatory CD4(+)CD25(+) T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105:735–741
9. Barik A, Lu Y, Sathyamurthy A, Bowman A, Shen C, Li L, Xiong WC, Mei L (2014) LRP4 is critical for neuromuscular junction maintenance. J Neurosci 34:13892–13905
10. Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V (2011) Comparison of IVlg and PLEX in patients with myasthenia gravis. Neurology 76:2017–2023
11. Benatar M, Kaminski H (2012) Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev 12:CD005081
12. Birmingham UoAa (2006) Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy. ClinicalTrials.gov NCT00294658
13. Brønberg MB, Wald J, Froshew DA, Feldman EL, Albers JW (1997) Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci 150:59–62
14. Buckley C, Douek D, Newsom-Davis J, Vincent A, Willcox N (2001) Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 50:64–72
15. Carr AS, Cardwell CR, McCarron PO, McConville J (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neuro 10:46
16. Castro D, Derisavifard S, Anderson M, Greene M, Iannaccone S (2014) Juvenile myasthenia gravis: a twenty-year experience. J Clin Neuromuscl Dis 11:95–102
17. Cavalcante P, Bernasconi P, Mantezza R (2012) Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol 25:621–629
18. Cea G, Benatar M, Verdugo RJ, Salinas RA (2013) Thymectomy for non-thymomatous myasthenia gravis. Cochrane Database Syst Rev 10:CD008111
19. Chan A, Lee DH, Liner R, Mohr A, Toyka K, Gold R (2007) Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol 254:1604–1606
20. Chuanig WY, Strobel P, Bohlender-Omkare NK, Riemark P, Nix W, Schalke B, Gold R, Opitz A, Klinker E, Inoue M, Muller-Hermelink HK, Sanu-Direskenel G, Beget P, Willcox N, Marx A (2014) Late-onset myasthenia gravis—CTLA4(low) genotype association and low-for-age thymic output of naïve T cells. J Autoimmun 52:122–129
21. Cifulloni L, Massey JM, Tucker-Lipscomb B, Sanders DB (2001) Mycohenophole motif for myasthenia gravis: an open-label pilot study. Neurology 56:97–99
22. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819–1828
23. Cole RN, Reddel SW, Gervasio OL, Phillips WD (2008) Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 63:782–789
24. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Ouyuela P, Panzara MA, Compston DA (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing multiple sclerosis: a randomised controlled trial. Lancet 380:1829–1839
25. Confavreux C, Sadr P, Grimaud J, Moreau T, Adeleine P, Aimard G (1996) Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 46:1607–1612
76. Hilton-Jones D (2007) When the patient fails to respond to treatment: myasthenia gravis. Pract Neurol 7:405–411
77. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365–368
78. Hoeltzenbein M, Weber-Schoendorfer C, Borisch C, Allignol A, Meister R, Schaefer C (2012) Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine. Reprod Toxicol 34:364–369
79. Hoffacker V, Schulz A, Tiesinga JJ, Gold R, Schalke B, Nix W, Kiefer R, Muller-Hermelink HK, Marx A (2000) Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood 96:3872–3879
80. Holhfeld R, Goebels N, Engel AG (1993) Cellular mechanisms in inflammatory myopathies. Baillieres Clin Neurol 2:617–635
81. Holhfeld R, Michels M, Heininger K, Besinger U, Toyka KV (1988) Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 38:258–261
82. Holhfeld R, Toyka KV, Besinger UA, Gerhold B, Heininger K (1985) Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 17:238–242
83. Howard JR Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, Mellion ML, Benatar MG, Farrugia ME, Wang JJ, Malhotra SS, Kissel JT (2013) A randomized, double-blind, placebo-controlled phase II study of ecuclizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 48:76–84
84. Huang H, Benoist C, Mathis D (2010) Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci USA 107:4658–4663
85. Huijbers MG, Zhang W, Kluoster R, Nis EH, Friese MB, Straathem KR, Thijessen PE, Vrolijk H, Plomp JJ, Vogels P, Losen M, Van der Maarel SM, Burden SJ, Verschueren JJ (2013) MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci USA 110:20783–20788
86. Imbach P, Barandun S, ’Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228–1231
87. Iorio R, Damato V, Alboini PE, Evoli A (2015) Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 262:1115–1119
88. Jaretski A 3rd, Penn AS, Younger DS, Wolff M, Olarte MR, Lovelace RE, Rowland LP (1988) ‘ ‘Maximal’ ’ thymectomy for myasthenia gravis. Results. J Thorac Cardiovasc Surg 95:747–757
89. Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE (2014) EFNS/ ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurology 21:687–693
90. Kirchner T, Schalke B, Melms A, von Kugelgen T, Muller-Hermelink HK (1986) Immunohistochemical patterns of non-neoplastic changes in the thymus in Myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol 52:237–257
91. Kisand K, Lilic D, Casanova JL, Peterson P, Meager A, Willcox N (2011) Mucocutaneous candidiasis and autoimmune against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol 41:1517–1527
92. Klooster R, Plomp JJ, Huijbers MG, Nis EH, Straathem JJ, Dettmers FJ, Hermans PW, Sleijpen K, Verrips A, Losen M, Martinez-Martinez P, De Baets MH, van der Maarel SM, Verschueren JJ (2012) Muscle-specific kinase myasthenia gravis
IgG4 autoantibodies cause severe neuromuscular junction dys-
function in mice. Brain 135:1081–1101
93. Kohler W, Bucka C, Klingel R (2011) A randomized and con-
trolled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher 26:347–355
94. Konishi T, Yoshiyama Y, Takamori M, Saida T (2005) Long-
term treatment of generalised myasthenia gravis with FK506
(tacrolium). J Neurol Neurosurg Psychiatry 76:448–450
95. Koziolek MJ, Kitze B, Mullhausen J, Muller GA (2013) Im-
munoadsorption in steroid-refractory multiple sclerosis. Atheroscler Suppl 14:175–178
96. Kupersmith MJ (2009) Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol 256:1314–1320
97. Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, Bartocciion F, Evoli A (2005) Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 64:536–538
98. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A (2008) IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain 131:1940–1952
99. Leite MI, Strobel P, Jones M, Micklem K, Moritz R, Gold R, Niki EH, Berrih-Aknin S, Scaravilli F, Canelhas A, Marx A, Newsom-Davis J, Willcox N, Vincent A (2005) Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 57:444–448
100. Lin PT, Martin BA, Weitmacker AB, So YT (2012) Myasthenogenicity of the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. J Neurol Neurosurg Psychiatry 83:935–940
101. McGoville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A (2004) Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 55:580–584
102. Meyer DM, Herbert MA, Sobhani NC, Tavakolian P, Duncan A, Bruns M, Korngut K, Williams J, Prince SL, Huber L, Wolfe G, Mack MJ (2009) Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transternal and minimally invasive approaches. Ann Thorac Surg 87:385–391
103. Michels M, Hohlfeld R, Hartung HP, Heineking K, Besinger UA, Toyka KV (1988) Myasthenia gravis: discontinuation of long-term azathioprine. Ann Neurol 24:798
104. Minami N, Fujiki N, Doi S, Shima K, Niiro M, Kikuchi S, Sasaki H (2011) Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J Neurol Sci 300:59–62
105. Muscle Study G (2008) A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 71:394–399
106. Muraishi N, Fujiki N, Doi S, Shima K, Niiro M, Kikuchi S, Sasaki H et al. (2011) Low-dose tacrolimus in the treatment of myasthenia gravis patients with low-dose tacrolimus. Intern Med 47:371–376
107. Nagamine F, Utsugisawa K, Obara D, Kondoh R, Terayama Y (2005) Efficacy of low-dose FK506 in the treatment of myasthenia gravis—a randomized pilot study. Eur Neurol 53:146–150
108. Novellino L, Longoni M, Spinelli L, Andretta M, Cozzi M, Faillace G, Vitellaro M, De Benedetti D, Pezzuoli G (1994) “Extended” thymectomy, without sternotomy, performed by extended transsternal and minimally invasive approaches. Ann Thorac Surg 87:385–391
109. Newsom-Davis J, Vincent A, Wilson SG, Ward CD, Pinching AJ, Hawkey C (1978) Plasmapheresis for myasthenia gravis. N Engl J Med 298:456–457
110. Nissenson AR (1977) Reduction of IgG levels in myasthenia gravis. N Engl J Med 296:819–820
111. Novellino L, Longoni M, Spinelli L, Andretta M, Cozzi M, Faillace G, Vitellaro M, De Benedetti D, Pezzuoli G (1994) “Extended” thymectomy, without sternotomy, performed by cervicotomy and thoracoscopic technique in the treatment of myasthenia gravis. Int Surg 79:378–381
112. O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309:1871–1874
113. O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309:1871–1874
114. O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309:1871–1874
115. O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309:1871–1874
116. Muscle Study G (2008) A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 71:394–399
117. Newsom-Davis J, Vincent A, Wilson SG, Ward CD, Pinching AJ, Hawkey C (1978) Plasmapheresis for myasthenia gravis. N Engl J Med 298:456–457
118. Nissenson AR (1977) Reduction of IgG levels in myasthenia gravis. N Engl J Med 296:819–820
119. Novellino L, Longoni M, Spinelli L, Andretta M, Cozzi M, Faillace G, Vitellaro M, De Benedetti D, Pezzuoli G (1994) “Extended” thymectomy, without sternotomy, performed by cervicotomy and thoracoscopic technique in the treatment of myasthenia gravis. Int Surg 79:378–381
120. O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309:1871–1874
121. O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309:1871–1874
122. O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309:1871–1874
123. O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309:1871–1874
124. Pascuzzi RM, Coslett HB, Johns TR (1984) Long-term corti-
costeroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 15:291–298
125. Pavezon A, Schosser B, Peters K, Cosma NC, Karakatsani A, Schalke B, Melms A, Kroger S (2012) Anti-LRP4 autoanti-
bodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 259:427–435
126. Pharmaceuticalcs A (2013) Safety and efficacy of eculizumab in refractory generalized myasthenia gravis (REGAIN study). ClinicalTrialsgov web-page NCT01997229
127. Pinching AJ, Peters DK (1976) Remission of myasthenia gravis following plasma-exchange. Lancet 2:1373–1376
128. Poeps-Guyon S, Christadoss P, Le Panse R, Guyon T, De Baets M, Wakkach A, Bidault J, Tzartos S, Berrih-Aknin S (2005)
Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol 174:5941–5949

129. Pompeo E, Tacconi F, Massa R, Mineo D, Nahmis S, Mineo TC (2009) Long-term outcome of thoracoscopic extended thymectomy for nonthymomatous myasthenia gravis. Eur J Cardiothorac Surg 36:164–169

130. Ponseti JM, Azem J, Fort JM, Lopez-Cano M, Vilallonga R, Buera M, Cervera C, Armengol M (2005) Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 64:1641–1643

131. Ponseti JM, Gamez J, Azem J, Lopez-Cano M, Vilallonga R, Armengol M (2008) Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann NY Acad Sci 1132:254–263

132. Pung A, Flink R, Askmark H, Stalberg EV (2006) Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve 34:111–115

133. Qureshi AI, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, Ulatowski JA, Krendel DA, Lasher RT (1999) Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 52:629–632

134. Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Macek M, Scholz SW, Corse A, Chaudhry V, Benatar M, Barohn RJ, McVey A, Pasnoor M, Dimachkie MM, Rowin J, Kissel JT, Freimer M, Kaminski HJ, Sanders DB, Lim C, Basu S, Maliszewski CR, Nickerson PA, Pascuzzi RM, Pestrunk A, Wulf C, Florence J, Blackmore D, Soloway A, Siddiqui Z, Muppadi S, Wolfe G, Richman D, Mezhi MM, Jiwa T, Oger J, Drachman DB, Traynor BJ (2015) A genome-wide association study of myasthenia gravis. JAMA Neurol 72:396–404

135. Robertson NP, Deans J, Compston DA (1998) Myasthenia gravis: a population based epidemiological study in Cambridge, England. J Neurol Neurosurg Psychiatry 65:492–496

136. Rodriguez M, Gomez MR, Howard FM Jr, Taylor WF (1983) Acetylcholine receptors in human thymic myoid cells and epithelial cells secrete thymic hormone but do not express class II antigens of the major histocompatibility complex. J Clin Invest 76:1140–1146

137. Romi F, Bo L, Skeie GO, Myking A, Aarli JA, Gilhus NE (2007) Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuromuscul Disord 12:504–510

138. Romi F, Aarli JA, Gilhus NE (2007) Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol 14:617–620

139. Romi F, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, Tsujihata M, Vincent A, Eguchi K (2005) Acetylcholine receptors loss post synaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57:289–293

140. Rothwell N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, Dichgans J (1997) Ocular myasthenia gravis: follow-up of 113 patients diagnosed after age 60. In: Richman DP (ed) Myasthenia Gravis and Related Diseases. New York, pp 777–780

141. Schroeder A, Linker RA, Gold R (1999) Plasmapheresis for neurological disorders. Expert Rev Neurother 9:1331–1339

142. Selin MF, Alkhayr OA, Lee AT, Lamb JA, Sussman J, Pirskanen-Matell R, Piehl F, Verschueren JJ, Kostera-Pruszczynski A, Szczudlik P, McKee D, Maniaol AH, Harbo HF, Lie BA, Melms A, Garchon HJ, Willcox N, Gregersen PK, Hammarström L (2015) Genome-wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A, and Identification of ZBTB10 and Three Distinct HLA Associations. Mol Med

143. Seybold ME (1998) Thymectomy in childhood myasthenia gravis. Ann N Y Acad Sci 841:731–741

144. Seybold ME, Drachman DB (1974) Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med 290:81–84

145. Shen C, Lu Y, Zhang B, Figueiredo D, Bean J, Jung J, Wu H, Barik A, Yin DM, Xiong WC, Mei L (2013) Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest 123:5190–5202

146. Shiogemoto K, Kubo S, Maruyama N, Hato N, Yamada H, Jie C, Kobayashi N, Momokoki N, Abe Y, Ueda N, Matsu S (2006) Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 116:1016–1024

147. Shiraiishi H, Tomotoma M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, Tsujihata M, Vincent A, Eguchi K (2005) Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57:289–293

148. Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, Tsujihata M, Vincent A, Eguchi K (2005) Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57:289–293

149. Siara J, Rudel R, Marx A (1991) Absence of acetylcholine-induced current in epithelial cells from thymus glands and thymomas of myasthenia gravis patients. Neurology 41:128–131

150. Skeie GO, Apostolski S, Eviol A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW, European Federation of Neurological Societies (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893–902

151. Sledak G, Melms A, Fea Gerneth (1998) Late onset myasthenia gravis– follow-up of 113 patients diagnosed after age 60. In: Richman DP (ed) Myasthenia Gravis and Related Diseases: Disorders of the Neuromuscular Junction. Ann NY Acad Sci, New York, pp 777–780

152. Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, Dichgans J (1997) Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 62:156–162

153. Stangel M, Gold R (2011) Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010. Nervenarzt 82:415–416
162. Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, Schalke B, Muller-Hermelink HK, Marx A (2004) Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 22:1501–1509

163. Strobel P, Chuang WY, Chuvpilo S, Zettl A, Katzenberger T, Kalbacher H, Rieckmann P, Nix W, Schalke B, Gold R, Muller-Hermelink HK, Peterson P, Marx A (2008) Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. Ann NY Acad Sci 1132:143–156

164. Strobel P, Helmreich M, Meniouakakis G, Lewin SR, Rudiger T, Bauer A, Hoffacker V, Gold R, Nix W, Schalke B, Elert O, Semik M, Muller-Hermelink HK, Marx A (2002) Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. Blood 100:159–166

165. Strobel P, Moritz R, Leite MI, Willcox N, Chuang WY, Gold R, Nix W, Schalke B, Kiefer R, Muller-Hermelink HK, Jaretzki III A, Newsom-Davis J, Marx A (2008) The ageing and myasthenic thymus: a morphometric study validating a standard procedure in the histological workup of thymic specimens. J Neuroimmunomunol 201–202:64–73

166. Strobel P, Murumagi A, Klein R, Luster M, Lahti M, Krohn K, Schalke B, Nix W, Gold R, Rieckmann P, Toyka K, Burek C, Rosenwald A, Muller-Hermelink HK, Pujoll-Borrell R, Meager A, Willcox N, Peterson P, Marx A (2007) Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol 211:563–571

167. Strobel P, Rosenwald A, Beyerdsorf N, Kerkau T, Elert O, Murumagi A, Sillanpaa N, Peterson P, Hummel V, Rieckmann P, Burek C, Schalke B, Nix W, Kiefer R, Muller-Hermelink HK, Marx A (2004) Selective loss of regulatory T cells in thymomas. Ann Neurol 56:901–904

168. Strober J, Cowan MJ, Horn BN (2009) Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol 66:659–661

169. Tackenberg B, Hemmer B, Oertel WH, Sommer N (2001) Immunosuppressive treatment of ocular myasthenia gravis. BioDrugs 15:369–378

170. Tackenberg B, Nitschke M, Willcox N, Zettl A, Nessler S, Schalke B, Nix W, Gold R, Rieckmann P, Toyka K, Burek C, Rosenwald A, Muller-Hermelink HK, Autoregulat 36:117–121

171. Tackenberg B, Schlegel K, Happel M, Eienbroker C, Gellert K, Oertel WH, Meager A, Willcox N, Sommer N (2009) Expanded TCR Vbeta subsets of CD8(+) T cells in late-onset myasthenia gravis: novel parallels with thymoma patients. J Neuroimmunomunol 216:85–91

172. Tada M, Shimohata T, Tada M, Oyake M, Igarashi S, Onodera O, Naruse S, Tanaka K, Tsuji S, Nishizawa M (2006) Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. J Neurol Sci 247:17–20

173. Thiruppathi M, Rowin J, Ganesh B, Sheng JR, Prabhakar BS, Mergioli MN (2012) Impaired regulatory function in circulating CD4(+)-CD25(high)/CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol 145:209–223

174. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K (1993) A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 681:539–551

175. Toyka KV, Brachman DB, Pestronek A, Kao I (1975) Myasthenia gravis: passive transfer from man to mouse. Science 190:397–399

176. Toyka KV, Drachman DB, Griffin DE, Pestronek A, Winkelstein JA, Fishbeck KH, Kao I (1977) Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 296:125–131

177. Tracy MM, McRae W, Millichap JG (2009) Graded response to thymectomy in children with myasthenia gravis. J Child Neurol 24:454–459

178. Travis WD, Brachman DB, Burke AP, Marx A, Nicholson AG (2015) WHO classification of tumours of the lung, pleura, thymus and heart. IARC Press 4th ed

179. Trontelj JV, Stalberg E (1995) Single fiber electromyography in studies of neuromuscular function. Adv Exp Med Biol 384:109–119

180. Tumani H (2008) Corticosteroids and plasma exchange in multiple sclerosis. J Neurol 255(Suppl 6):36–42

181. Tzartos SJ, Lindstrom J (1980) Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci USA 77:755–759

182. Van de Velde RL, Friedman NB (1978) Thymic myoid cells and myasthenia gravis. Am J Pathol 95:347–368

183. Vernino S, Salomao DR, Habermann TM, O’Neill BP (2005) Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 65:639–641

184. Vincent A, Jacobson L, Shillito P (1994) Response to human acetylcholine receptor alpha 138–199: determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunol Lett 39:269–275

185. Wakkach A, Poea S, Chastre E, Gaspach C, Lecerf Y, De La Porte S, Tzartos S, Coulombe A, Berrih-Aknin S (1999) Establishment of a human thymic myoid cell line. Phenotypic and functional characteristics. Am J Pathol 155:1229–1240

186. Willcox N, Leite MI, Kadota Y, Jones M, Meager A, Subrahmanya P, Dasgupta B, Morgan BP, Vincent A (2008) Autoimmunizing mechanisms in thymoma and thymus. Ann NY Acad Sci 1132:163–173

187. Willcox N, Schlupe M, Ritter MA, Schuurman HJ, Newsom-Davis J, Christensson B (1987) Myasthenic and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset? Am J Pathol 127:447–460

188. Witte AS, Cornblath DR, Parry GJ, Lisak RP, Schatz NJ (1986) Monitoing azathioprine therapy in myasthenia gravis. Neurology 36:1533–1534

189. Witte AS, Cornblath DR, Schatz NJ, Lisak RP, Mei L (2014) Autoantibodies to agrin in myasthenia gravis with mycophenolate mofetil. Neurology 83:109–119

190. Witte AS, Cornblath DR, Schatz NJ, Lisak RP (1986) Monitoring azathioprine therapy in myasthenia gravis. Neurology 36:1533–1534

191. Wolfle GL, Kamiński H, Jaretzki A 3rd, Swan A, Newsom-Davis J (2003) Development of a thymectomy trial in nonthymomatos myastenia gravis patients receiving immunosuppressive therapy. Ann NY Acad Sci 998:473–480

192. Yeh JH, Chiu HC (2000) Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol 247:510–513

193. Yim AP, Kay RL, Ho JK (1995) Video-assisted thoracoscopic thymectomy for myasthenia gravis. Chest 108:1440–1443

194. Yoshikawa H, Kiciu T, Saida T, Takamori M (2011) Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. Neuroradiology 55:1533–1534

195. Zeitler H, Ulrich-Merzenich G, Hoffmann L, Kornblum C, Rieckmann P, Burek C, Schalke B, Nix W, Kiefer R, Muller-Hermelink HK, Marx A (2007) Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol 211:563–571

196. Zhang B, Shen C, Bealmear B, Ragheb S, Xiong WC, Lewis RA, Lisak RP, Mei L (2014) Autoantibodies to agrin in myasthenia gravis patients. PLoS One 9:e91816
196. Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA, Xiong WC, Lisak RP, Tzartos SJ, Mei L (2012) Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 69:445–451

197. Zhou L, McConville J, Chaudhry V, Adams RN, Skolasky RL, Vincent A, Drachman DB (2004) Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 30:55–60

198. Zinman L, Ng E, Bril V (2007) IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68:837–841

199. Zisimopoulou P, Evangelakou P, Tzartos I, Lazaridis K, Zouvelou V, Mantegazza R, Antozzi C, Andreotta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Frenkian Cuvelier M, Stojkovic T, DeBaets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczynk A, Szczudlik P, Szyulk B, Lavnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Tzartos SJ (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52:139–145